Bayer Launches Kogenate FS in Middle East

|

kogenate fsBayer HealthCare announced today the official launch of Kogenate FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose) in the Middle East. Kogenate FS is Bayers advanced recombinant factor VIII product for the treatment of hemophilia A, a bleeding disorder characterized by deficient or defective levels of the blood clotting protein known as factor VIII.

The launch was announced at "Hemophilia Care: Past, Present and Future", a medical symposium on the topic of hemophilia and its treatment. The symposium involved more than 100 physicians from across the Middle East who attended to learn more about the latest research and treatment for people living with hemophilia.

The program was held at the J.W. Marriott in Dubai. Information was presented about Bayers Kogenate products, representing nearly two decades of clinical use, and more than six billion patient infusions without a documented case of infectious agent transmission. As a recombinant form of factor VIII, Kogenate FS is not derived from human plasma and therefore the theoretical risk of pathogen contamination is extremely remote. Additional steps taken by Bayer to further reduce the theoretical risk by infectious agents, such as viruses or pathogenic prions, includes an innovative manufacturing process which includes six viral clearance steps.

Habib Dable, Vice President, Sales & Marketing Japan, Canada & Developing Markets, Bayer HealthCare Pharmaceuticals, Hematology/Cardiology, expressed his expectation of the new drug's wide reach now that it is available to the Middle East hemophilia community. "We are pleased that our product, which has demonstrated its safety and effectiveness in other countries, is now available for doctors and patients across the Middle East," said Dable. "We are confident that this will be an important step forward for improving patient outcomes and quality of life." Medical experts who participated in the symposium and their presentations were as follows: Professor Victor Blanchette, Chief of the Division of Hematology/Oncology at the Hospital for Sick Children and Professor of Pediatrics at the University of Toronto, addressed the new advances achieved in the treatment of hemophilia, pointing out that collaborative efforts are underway between the Middle East and countries such as Canada to work together to improve the quality of life for people living with hemophilia in the region.

Dr Magdy El Ekiaby, World Federation Hemophilia (WFH) Medical Volunteer, Member of the WFH Twinning Committee, and Head of Blood Bank Hospital Shabrawishy Hospital, discussed opportunities for the hemophilia community and industry leaders such as Bayer to work together on programs and services that increase the overall value of the products they provide.

In addition to the valuable detailed report on hemophilia treatment, the scientific conference provided more highlight on prophylaxis and on demand treatment for hemophilia patients was presented by Dr. Muhammad Faisal Khanani, Consultant Pediatric Hematology/Oncology Tawam Hospital UAE. He has presented review of literature which shows the benefits of using prophylaxis in Managing severe hemophilia patients (injecting anti-hemophilic drug preferably recombinant one regardless there is a bleeding or not) Professor M.S. El Alfy, Director of the Hemophilia Center at Ain Shams University, Egypt, drew attention to the need to further improve awareness of hemophilia so that patients can be properly tested, diagnosed, and then receive effective treatment. This may also lead to better information about the prevalence of hemophilia in the region.

In his welcome speech at the conference, Dr. Gamal Mikhail, Bayer HealthCare Senior Representative for the Middle East, discussed the leading role Bayer will take in the region as a reputed global leader in hemophilia. "Through accurate diagnosis together with suitable preventive measures and effective medication, Bayer will build on our long history of supporting patients and physicians to setting new standards of care."

About Kogenate FS

Kogenate FS [Antihemophilic Factor (Recombinant), Formulated with Sucrose] is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse event was local site injection site reactions. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate FS.

About Hemophilia

Approximately 400,000 people around the world have hemophilia. Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. The disease is caused by deficient or defective blood coagulation proteins, known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX.

About Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the worlds leading, innovative companies in the health care and medical products industry based in Leverkusen/Germany. In 2005, the Bayer HealthCare subgroup generated sales amounting to some 9.4 billion Euro. Bayer HealthCare employed 33,800 people worldwide in 2005.

The company combines the global activities of the divisions Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Since January 1, 2006 the new Pharmaceutical Division consists of the former Biological Products and Pharmaceutical Division and now comprises three business units: Hematology/Cardiology, Oncology and Primary Care.

source - Al Bawaba